Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects
- Conditions
- Healthy Subjects
- Interventions
- Registration Number
- NCT04411875
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Brief Summary
The single-dose randomized, open-label, two-period crossover study was executed in the Phase I Clinical Research Center of the Affiliated Hospital of Qingdao University. According to the random table generate by SAS 9.4, the subjects were divided into two groups at the ratio of 1:1. The select qualified volunteers were hospitalized in the Phase I Clinical Research Center, and fasted for 10 hours overnight until administration. The medicine was swallowed with 240 ml water at room temperature. Blood samples were taken before administration and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168 hours after administration. The samples were centrifuged at 1,800 g for 10 min at 4 °C to separate the plasma. The plasma samples were divided into two aliquots and stored at -80 °C until bioanalysis. The half-life of levamlodipine is 30 \~ 50 hours. Washout period, the interval between two administration, is 21 days. In the two periods, the operation was kept the same.
Moreover, in high fat meal group, the high-fat breakfast was arranged within half an hour before taking the medicine. Other procedures were the same as those in the fasting group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
- Healthy male or female aged 18 and above.
- The body mass index is in the range of 18.6-28.5 kg/m2 (including the critical value). The weight of male is not less than 50.0 kg, and that of female is not less than 45.0 kg.
- The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG, breath test for alcohol, drug abuse test.
- The subjects have no family planning within 3 months and could select contraceptive method.
- Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.
- Being allergy to the study medications, smoking, alcohol abuse.
- Participation in another clinical trial within 3 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Levamlodipine Levamlodipine 5 mg levamlodipine test formulation at a single dose of 5 mg Amlodipine Amlodipine 10 mg amlodipine reference formulation at a single dose of 10 mg
- Primary Outcome Measures
Name Time Method Area under the plasma concentration versus time curve (AUC)0-t 64 days Evaluation of Area under the plasma concentration versus time curve (AUC)0-t
Area under the plasma concentration versus time curve (AUC)0-∞ 64 days Evaluation of Area under the plasma concentration versus time curve (AUC)0-∞
Peak Plasma Concentration (Cmax) 64 days Evaluation of Peak Plasma Concentration (Cmax)
- Secondary Outcome Measures
Name Time Method Incidence of abnormal pulse 64 days Temperature the pulse
Incidence of abnormal electrocardiogram waveform 64 days Electrocardiogram inspection
Incidence of Treatment-Emergent Adverse Events 64 days Collection of adverse events
Incidence of abnormal blood pressure 64 days Monitor both systolic and diastolic blood pressure
Incidence of abnormal temperature 64 days Monitor the temperature
Trial Locations
- Locations (1)
Phase Ⅰ Clinical Research Center
🇨🇳Qingdao, Shandong, China